15.3 C
New York
Monday, September 20, 2021

Why the electroCore, Inc (ECOR) stock is rising today?

Brief


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


electroCore, Inc (ECOR) shows a gain in its stock during the recent. It is a commercial stage bioelectric medicine company. ECOR uses its platform non-invasive vagus nerve stimulation therapy to improve patient outcomes, initially directed towards the treatment of multiple condition in neurology. The company’s main focus is towards the use of preventive treatment of cluster headache and acute treatment of pain associated with episodic cluster headache in adult patients. As well as they also aim to provide acute and preventive treatment of migraine for both adolescent and adult patients.

Recent developments

An announcement has been made by the company that the management is going to participate in two upcoming investor conferences. The first conference is H.C. Wainwright Global Life Sciences Conference happening on March 9 and 10. The second conference it is going to attend is M Vest LLC and Maxim Group LLC Emerging Growth Virtual Conferencewhich is scheduled on 17 and 18 of March.

Also on 28 February, ECOR announced that they have signed an exclusive agreement with Medistar PTY limited. The agreement has been followed by regulatory approval in Australia.

What next?

Now Medistar will work as the exclusive distributor of ECOR in Australia for their gammaCore Sapphire non-invasive vagus nerve stimulator. The main purpose is to supply therapies to patients who are suffering from headache disorders. It is a device free of drug with no side-effects.  The Australian Therapeutic Goods Administration (TGA) approved the promotion of gammacore sapphire after which the company made its official announcement.

This agreement between ECOR and Medistar is valid for next three years with the required customary terms and conditions and also has minimum purchase requirement. Medistar is set to launch the grammaCore Sapphire at the 2021 ANZHS annual meeting.

Conclusion

This agreement followed by the company’s participation in two upcoming investor conference has definitely attracted the attention of investors. The future looks promising for the company because of the product they have invented and has given a boost to the overall working.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.